Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Frontline Avelumab Maintenance Provides Prolonged Survival Benefit in Urothelial Carcinoma

May 10th 2023

Shilpa Gupta, MD, discussed the significance of the phase 3 JAVELIN Bladder 100 trial in urothelial cancer, updated data on the use of avelumab maintenance therapy following first-line chemotherapy in this population, and how this research could better inform patient-provider conversations about this option in the clinic.

Dr Park on Navigating of Later-line Treatment Options in Metastatic Urothelial Carcinoma

May 9th 2023

Chandler Park, MD, MSc, FACP, discusses the navigation and selection of later-line treatments for patients with metastatic urothelial carcinoma.

Pembrolizumab Could Delay Radical Cystectomy in BCG-unresponsive, High-risk NMIBC

May 7th 2023

Eric A. Singer, MD, discusses the findings from cohort B of KEYNOTE-057 and explains why systemic therapy with pembrolizumab could be beneficial for patients with Bacillus Calmette-Guérin–unresponsive, high-risk, papillary-only non–muscle invasive bladder cancer who hope to avoid radical cystectomy.

Dr Katz on a Cystoscopic Cryocatheter in Bladder Cancer

May 5th 2023

Aaron E. Katz, MD, discusses the rationale for and findings from a preclinical study evaluating the efficacy of a novel cystoscopic cryocatheter for in situ bladder cancer destruction.

Exploratory IMvigor130 Data Support Single-agent Atezolizumab in Select Patients With Urothelial Carcinoma

May 5th 2023

Aristotelis Bamias, MD, discusses the efficacy and safety data from the final OS analysis of the IMvigor130 trial and emphasizes the clinical implications of this research in metastatic urothelial cancer.

TAR-200 Monotherapy Displays Early Efficacy in BCG-Unresponsive NMIBC

May 5th 2023

Sia Daneshmand, MD, discusses the rationale for investigating TAR-200 for the treatment of patients with Bacillus Calmette-Guérin-unresponsive, high-risk non–muscle-invasive bladder cancer, expands on the preliminary efficacy and safety data from the SunRISe-1 trial, and more.

FDA Grants 501K Clearance to Bladder EpiCheck for Surveillance in NMIBC

May 5th 2023

The FDA has granted 510K clearance to Bladder EpiCheck for use as a noninvasive method for surveillance of tumor recurrence in previously diagnosed patients with non–muscle invasive bladder cancer, in conjunction with cystoscopy.

Dr Son on Urinary and Bowel Anastomotic Leak in Bladder Cancer

May 4th 2023

Young Son, PGY3, discusses the future implications of findings from a study investigating the association between neoadjuvant chemotherapy and increased urinary and bowel anastomosis failure in patients with bladder cancer who are undergoing radical cystectomy.

Goals of Maintenance Therapy in Metastatic Urothelial Carcinoma

May 4th 2023

A panel of four key opinion leaders discuss the role of maintenance therapy in metastatic urothelial carcinoma and how its use has impacted the treatment landscape.

Metastatic Urothelial Carcinoma: Number of Frontline Chemotherapy Cycles

May 4th 2023

A brief review of the appropriate number of chemotherapy cycles to utilize in the setting of metastatic urothelial carcinoma.

Dr Gupta on First-line Avelumab Maintenance in Advanced Urothelial Carcinoma

May 3rd 2023

Shilpa Gupta, MD, discusses findings from a long-term analysis of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

Dr Dhanji on the Effect of Hypertension on Survival Outcomes in Upper Tract Urothelial Carcinoma

May 2nd 2023

Sohail Dhanji, MD, discusses the effect of preoperative hypertension on survival outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma, and the importance of hypertension control in this population.

Dr Singer on Systemic Pembrolizumab Monotherapy in BCG-unresponsive High-Risk NMIBC

May 2nd 2023

Eric A. Singer, MD, discusses the use of systemic pembrolizumab monotherapy in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle invasive bladder cancer.

Pembrolizumab Monotherapy Demonstrates Clinical Efficacy in High-risk NMIBC

May 1st 2023

Treatment with pembrolizumab monotherapy resulted in stable long-term disease-free survival rates in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer.

TAR-200 Produces High CR Rates, Tolerability in BCG-unresponsive NMIBC

May 1st 2023

Treatment with TAR-200 produced complete responses and was well tolerated in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer, according to preliminary data from the phase 2b SunRISe-1 trial.

Dr Li on the Use of CG0070 Plus Pembrolizumab in BCG-Unresponsive Non–muscle Invasive Bladder Cancer

April 29th 2023

Roger Li, MD, discusses phase 2 data with the combination of CG0070 and pembrolizumab in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.

Phase 2 Data Show Clinical Activity With CG0070 Plus Pembrolizumab in NMIBC

April 29th 2023

Cretostimogene grenadenorepvec in combination with pembrolizumab produced high complete response rates with a tolerable safety profile in patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.

Long-Term JAVELIN Bladder 100 Data Support Avelumab Maintenance in Advanced Urothelial Carcinoma

April 28th 2023

First-line avelumab maintenance therapy prolonged survival in patients with advanced urothelial carcinoma, regardless of response to first-line chemotherapy, according to findings from an exploratory subgroup analysis of the phase 3 JAVELIN Bladder 100 trial.

68Ga-FAP-2286 PET Imaging Influences Bladder Cancer Treatment Decisions

April 28th 2023

The use of 68Ga-FAP-2286 PET imaging may improve treatment selection and response assessment in patients with bladder cancer, according to findings from a pilot study evaluating the diagnostic performance of this imaging technology.

Dr Katims on the Utility of the MSK-ACCESS Assay in Node+ MIBC

April 28th 2023

Andrew Katims, MD, MPH, discusses the utility of a circulating tumor DNA assay (MSK-ACCESS) in patients with node-positive muscle-invasive bladder cancer.